MapmyGenome launches its affordable Pharmacogenomics solution MedicaMap, covering more than 165 drugs.

MapmyGenome has officially launched MedicaMap — an affordable pharmacogenomics solution covering more than 165 drugs — making precision medicine accessible to a wider population of Indian patients and healthcare providers. The launch represents a major step forward in bringing the benefits of pharmacogenomic testing to mainstream Indian healthcare.

Affordability as a Core Principle

A key differentiator of MedicaMap is its pricing — designed to be accessible to a broader population than previous pharmacogenomic testing options in India. "Pharmacogenomic testing has historically been expensive and available only in specialized centers," said Anu Acharya, CEO of MapmyGenome. "MedicaMap changes that. We believe every Indian patient deserves to know how their genes affect their medications."

Comprehensive Drug Coverage

MedicaMap covers 165+ drugs across cardiology, psychiatry, neurology, oncology, pain management, and other therapeutic areas. Key drug categories include anticoagulants (warfarin), antiplatelets (clopidogrel), antidepressants and antipsychotics, antiepileptics (carbamazepine, phenytoin), statins, opioid analgesics (codeine, tramadol), and chemotherapy agents (5-FU, irinotecan, tamoxifen).

Simple At-Home Testing

MedicaMap uses a simple saliva sample collected at home — no blood draw, no clinic visit required. The sample is processed in MapmyGenome's NABL-certified laboratory, with results delivered as a comprehensive digital report with actionable drug-specific recommendations.

Supporting Healthcare Providers

MedicaMap is designed to support both patients and healthcare providers. Doctors receive a clinically formatted report with specific recommendations for each covered medication — making it easy to integrate pharmacogenomic insights into prescribing decisions. MapmyGenome also offers genetic counselor consultations to help patients and providers interpret results.